Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Kura Oncology (KURA)
NASDAQ:KURA
Holding KURA?
Track your performance easily
KURA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$7.41 - $24.17
Previous Close$20.16
Volume456.82K
Average Volume (3M)669.34K
Market Cap
$1.54B
Enterprise Value$1.07B
Total Cash (Recent Filing)$491.52M
Total Debt (Recent Filing)$16.73M
Price to Earnings (P/E)―
Beta1.47
Next Earnings
Oct 31, 2024EPS Estimate
-$0.63Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.23
Shares Outstanding76,634,496
10 Day Avg. Volume451,917
30 Day Avg. Volume669,341
Standard Deviation0.17
R-Squared0.06
Alpha0.00778
Financial Highlights & Ratios
Price to Book (P/B)3.06
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-8.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-7.84
Forecast
1Y Price Target
$30.89Price Target Upside52.47% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
Kura Oncology News
PremiumCompany Announcements
Kura Oncology Welcomes New Director Michael Vasconcelles
Bulls Say, Bears Say
Bulls Say
Clinical Development ProgressKura's menin inhibitor ziftomenib shows impressive progress, indicating a transformative year ahead with its potential as a best-in-class therapy for leukemia.
Financial StabilityKura Oncology's robust cash position, with a financial runway extending into 2027, ensures the company's stability and supports ongoing research and development.
Trial Enrollment And InterestThe rapid completion of Kura’s AML treatment trial enrollment demonstrates strong interest and momentum, suggesting a promising future for the drug.
Bears Say
Clinical TrialsPotential risks include failed clinical trials which could affect the company's ability to continue drug development.
Financial PerformanceKura reported no revenue with R&D and SG&A expenses higher than estimates.
RevenueKura reported no revenue for a recent quarter.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
KURA FAQ
What was Kura Oncology’s price range in the past 12 months?
Kura Oncology lowest stock price was $7.41 and its highest was $24.17 in the past 12 months.
What is Kura Oncology’s market cap?
Currently, no data Available
When is Kura Oncology’s upcoming earnings report date?
Kura Oncology’s upcoming earnings report date is Oct 31, 2024 which is in 43 days.
How were Kura Oncology’s earnings last quarter?
Kura Oncology released its earnings results on Aug 08, 2024. The company reported -$0.59 earnings per share for the quarter, beating the consensus estimate of -$0.626 by $0.036.
Is Kura Oncology overvalued?
According to Wall Street analysts Kura Oncology’s price is currently Undervalued.
Does Kura Oncology pay dividends?
Kura Oncology does not currently pay dividends.
What is Kura Oncology’s EPS estimate?
Kura Oncology’s EPS estimate is -$0.63.
How many shares outstanding does Kura Oncology have?
Kura Oncology has 76,634,500 shares outstanding.
What happened to Kura Oncology’s price movement after its last earnings report?
Kura Oncology reported an EPS of -$0.59 in its last earnings report, beating expectations of -$0.626. Following the earnings report the stock price went down -0.785%.
Which hedge fund is a major shareholder of Kura Oncology?
Among the largest hedge funds holding Kura Oncology’s share is Deerfield Management Company, LP. It holds Kura Oncology’s shares valued at 111M.
---
Kura Oncology Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$30.89 (52.47% Upside)
$30.89 (52.47% Upside)
Blogger Sentiment
Bullish
KURA Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 79.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 3.5%
Last 30 Days >0.1%
Last 30 Days >0.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
103.84%
12-Months-Change
Fundamentals
Return on Equity
-39.27%
Trailing 12-Months
Asset Growth
4.12%
Trailing 12-Months
Company Description
Kura Oncology
Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia; KO-947 which is an ERK inhibitor for MAPK Pathway Tumors; and KO-539 which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in La Jolla, CA.
---
KURA Company Deck
---
KURA Earnings Call
Q2 2024
0:00 / 0:00
---
KURA Stock 12 Month Forecast
Average Price Target
$30.89
▲(52.47% Upside)
Technical Analysis
Best Analysts Covering KURA
1 Year
1 Year Success Rate
9/14 ratings generated profit
1 Year Average Return
+48.37%
reiterated a buy rating last month
Copying Joseph Pantginis's trades and holding each position for 1 Year would result in 64.29% of your transactions generating a profit, with an average return of +48.37% per trade.
---